Related Party [Axis]
Zander [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Class of Stock [Axis]
Common Stock
Notes Payable [Axis]
David Koos
Blackbriar Partners
Blackbriar Partners #2
Blackbriar Partners #3
Blackbriar Partners #4
Equity Components [Axis]
Accumulated Deficit during the Development Stage
Contributed Capital
Series AA Preferred
Series AAA Preferred
Series B Preferred
Non Voting Convertible Preferred
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Non Controlling interest In Subsidiary
Series AA
Series AAA
Series B
NonVoting [Member]
Preferred Stock [Member]
Business Acquisition [Axis]
Entest CA
Dunhill Ross Partners, Inc.
Regen Biopharma, Inc [Member]
Notes Receivable [Axis]
Regen BioPharma Inc.
Zander M Stock [Member]
David Koos [Member]
Sherman Family Trust
Bio Technology Partners Business Trust [Member]
Bio Matrix Scientific Group [Member]
Bostonia Partners [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Is Entity a Well-known Seasoned Issuer?
Is Entity a Voluntary Filer?
Is Entity's Reporting Status Current?
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Entity Ex Transition Period
Entity Shell Company
Entity Public Float
Entity Common Stock, Shares Outstanding
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement [Table]
Statement [Line Items]
ASSETS
Current Assets
Cash
Accrued Interest Receivable
Current Portion of Prepaid Expenses
Accrued Rent Receivable
Total Current Assets
OTHER ASSETS
Available for Sale Securities
Long Term Portion Prepaid Expenses
TOTAL ASSETS
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts Payable
Notes Payable
Due to Other
Unearned Rental Income
Bank Overdraft
Accrued Expenses
Total Current Liabilities
TOTAL LIABILITIES
STOCKHOLDERS' EQUITY
Common Stock, authorized 500,000,000 shares as of August 31, 2017 and August 31, 2018; issued and outstanding 46,670,472(par value $0.0001) as of August 31, 2017 and 49,170,472 as of August 31, 2018
Preferred Stock
Additional Paid in Capital
Contributed Capital
Accumulated Deficit
Accumulated Other Comprehensive Income
Total Stockholders' Equity Entest Biomedical, Inc.
Non Controlling Interest Zander Therapeutics Inc.
Stockholders Equity
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Income Statement [Abstract]
REVENUES
TOTAL REVENUE
COSTS AND EXPENSES
Research and Development
Rent Costs
General and Administrative
Consultant's Expenses
Total Costs and Expenses
OPERATING LOSS
OTHER INCOME AND EXPENSE
Rental Income
Interest Income
Gain on Write Off of Accounts Payable
Loss on Issuance of Stock Below Fair Value
Gain on Deconsolidation of Zander
Equity in Losses of Zander
Gain on Sale of Securities
Interest Expense
TOTAL OTHER INCOME AND EXPENSE
LOSS BEFORE INCOME TAXES
Income Taxes
NET LOSS
NET LOSS from continuing Operations
Less: (Net Income) Loss attributable to non controlling interest in Zander Therapeutics, Inc.
NET LOSS available to common shareholders
BASIC AND DILUTED EARNINGS (LOSS) PER SHARE FROM CONTINUING OPERATIONS
WEIGHTED AVERAGE NUMBER COMMON SHARES OUTSTANDING
Statement of Comprehensive Income [Abstract]
Net Income (Loss)
Add:
Unrealized Gains on Securities
Less:
Unrealized Losses on Securities
Comprehensive Income attributable to Non Controlling Interest
Total Other Comprehensive income (Loss)
Comprehensive Income
Statement of Cash Flows [Abstract]
OPERATING ACTIVITIES
Net (Loss)
Adjustments to reconcile net loss to net cash used by operating activities:
Increase (Decrease) in stock of subsidiary issued to employees
Increase (Decrease) in stock of subsidiary issued to consultants
Increase (Decrease) in Additional paid in capital
Increase (Decrease) in Issuance of Stock below Fair Value
Increase (Decrease) in Preferred Stock issued for expenses
Increase (Decrease) in Preferred Stock issued to Consultants
(Increase) Decrease in Gain attributable to Deconsolidation
(Increase) Decrease Cash Lost in Deconsolidation
Equity in Losses of Zander
Increase (Decrease) Common Stock issued to Consultants
Changes in Operating Assets and Liabilities
(Increase) Decrease in Prepaid Expenses
Increase(Decrease) in Unearned Rent
Increase (Decrease) in Accounts Payable
(Increase) Decrease in Accrued Rental Income Receivable
Increase (Decrease) in Accrued Expenses
(Increase) Decrease in Accrued Interest Receivable
(Increase) Decrease in Notes Receivable
Net Cash Provided (Used) in Operating Activities
Net Cash Provided ( Used) in Investing Activities:
Securities Purchased for Cash
Gain on Sale of Securities received prior to deconsolidation
Net Cash Provided (Used In) Investing Activities
FINANCING ACTIVITIES
Common Stock issued for cash
Common Stock of Subsidiary issued for cash
Increase (Decrease) in Notes Payable
Increase(Decrease) Bank Overdraft
Increase (Decrease) in Contributed Capital
Net Cash Provided by Financing Activities
Net (Decrease) Increase in Cash
Cash at Beginning of Period
Cash at End of Period
Supplemental Disclosure of Non CashInvesting and Financing Activities:
Common Stock Issued for Debt
Preferred Stock issued for Debt
Beginning balance, Shares
Beginning balance, Amount
Common Shares issued to Consultant
Common Shares issued to Consultant, Amount
Common Shares issued for Debt, Shares
Common Shares issued for Debt, Amount
Common Shares issued for Debt, Shares
Common Shares issued for Debt, Amount
Common Shares issued to Consultant
Common Shares issued to Consultant, Amount
Series B Preferred shares issued to consultant
Series B Preferred shares issued to consultant, Amount
Series B Preferred shares issued to consultant
Series B Preferred shares issued to consultant, Amount
Series B Preferred shares issued to consultant
Series B Preferred shares issued to consultant, Amount
Common Stock Issued for Cash
Common Stock Issued for Cash, Amount
Common Stock of Subsidiary sold for Cash
Common Shares issued to Consultant
Common Shares issued to Consultant, Amount
Shares issued for accrued expenses
Shares issued for accrued expenses, Amount
Shares issued for Debt, Shares
Shares issued for Debt, Amount
Beneficial Conversion Feautures recognized
Amortization of Beneficial Conversion Feauture
Preferred Shares of Subsidiary issued to consultants
Preferred Shares of Subsidiary issued to employees
Common Shares issued for NonVoting Convertible Preferred Shares
Common Shares issued for NonVoting Convertible Preferred Shares, Amount
Common Stock of Subsidiary issued for Cash
Common Stock of Subsidiary issued for Cash
Common Stock of Subsidiary issued for Cash
Common Shares of Subsidiary issued to Consultant
Preferred Shares of Subsidiary issued to consultants
Common Shares issued to Consultant
Common Shares issued to Consultant, Amount
Shares issued for accrued expenses
Shares issued for accrued expenses, Amount
Beneficial Conversion Feautures recognized
Amortization of Beneficial Conversion Feauture
Preferred Shares of Subsidiary issued to consultants
Restricted Stock Expense Recognized
Accumulated Other Comprehensive Income Recognized
Loss on Issuance below Fair Value
Declaration of property Dividend
Payment of Property Dividend
Elimination of Noncontrolling Interest upon deconsolidation
Sale of Securities of Securities Available for Sale
Net Loss for Year
Non Controlling Interest in Subsidiary
Increase in Contributed Capital Year
Ending balance, Shares
Ending balance, Amount
Accounting Policies [Abstract]
Organization and Description of Business
Summary of Significant Accounting Policies
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recent Accounting Pronouncements
Going Concern
Debt Disclosure [Abstract]
Notes Payable
Related Party Transactions [Abstract]
Related Party Transactions
Income Tax Disclosure [Abstract]
Income Taxes
Business Combinations [Abstract]
Acquisition of Entest CA
Acquisition of the Assets of Pet Pointers, Inc.
Disposition of the Assets of Pet Pointers, Inc.
Notes to Financial Statements
Deconsolidation of Zander Therapeutics, Inc.
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Investment Securities
Equity [Abstract]
Stockholders Equity
Stock Transactions
Subsequent Events [Abstract]
Subsequent Events
Basis of Accounting
Principles of Consolidation
Use of Estimates
Cash Equivalents
Property and Equipment
Fair Value of Financial Instruments
Income Taxes
Basic Earnings (Loss) Per Share
Notes Payable
Deferred Tax Assets
Schedule of deconsolidation
Summary Information For Zander Therapeutics ,Inc
Comprehensive Income
Acquisition of share capital of Company
Property and Equipment
Notes payable
Due to TheraCyte, Inc
Valuation allowance
Net (loss)
Notes Payable
Lines of credit
Notes payable
Interest rate per annum
Note Due Date
Amount due
Note receivable
Monthly rent revenue
License fee
Preferred stock purchased
Cash consideration for purchase of Preferred Stock
Preferred Stock Issued
Stock issued for consideration, Shares
Stock issued for consideration, Value
Monthly Sublease income
Deferred tax assets:
Net operating tax carry forwards
Other
Gross deferred tax assets
Valuation allowance
Net deferred tax assets
Deferred tax asset
Net operating loss carry forwards
Net operating loss carry forwards acquired in the reverse acquisition of Entest BioMedical, Inc.
Net operating loss carry forwards attributable to Entest BioMedical, Inc.
Deferred tax assets, net valuation allowance
Federal Corporate Rate income tax
Acquisition of Entest CA
Newly issued common shares of Entest
Cancellation of shares of common stock
Acquisition of cash
Acquisition of common shares
Maximum payment to creditor
Monthly installments to creditor
Maximum payment to additional creditors
Monthly installments to additional creditors
Monthly payment to McDonald
Asset disposal, property plant and equipment
Impairment of goodwill
Obligated payment, Closing of agreement
Fair Value of Intellectual Property
Prepaid Expenses
Due from Entest
Enterprise Value
Less: Total Debt
Enterprise Value available to Shareholders
Per Share
Revenue
Operating Loss
Net Loss
Portion of Net Loss attributable to Entest
Dividend in kind
Common shares par value
Distribution Date
Gain on deconsolidation
Equity Method stock remaining
Decrease in carrying value
Ownership Percentage
Office monthly lease payments
Investment Securities, Basis
Investment Securities, Fair Value
Investment Securities, Total Unrealized Losses
Investment Securities, Net Unrealized Loss during the quarter
Liquidation terms
Legal Entity [Axis]
Transaction Type [Axis]
Stock issued upon conversion
Preferred Shares Redeemed
Number of shares issued to satisfy of accrued interest
Number of shares issued to satisfy of prepaid rent
The return by Mr. Rick Plote of shares of Entest’s common stock previously issued to him by Entest for cancellation.
Amount of the required periodic payments including both interest and principal payments to additional creditors.
Due To Other.
Assets, Current
Assets
Due to Other
Liabilities, Current
Liabilities
Other Additional Capital
Stockholders' Equity Attributable to Parent, Qualified for Net Capital
Liabilities and Equity
Costs and Expenses
Interest Expense
Other Nonoperating Income (Expense)
Other Comprehensive Income (Loss), before Tax
LossOnIssuanceOfStockBelowFairValue
Cash, Period Increase (Decrease)
Cash and Cash Equivalents, at Carrying Value
Shares, Outstanding
Stockholders' Equity Attributable to Parent
DebtConversionConvertedInstrumentSharesIssued2
DebtConversionConvertedInstrumentAmount2
StockIssuedDuringPeriodSharesIssuedForServices2
StockIssuedDuringPeriodValueIssuedForServices2
SeriesBPreferredSharesIssuedToConsultant2
SeriesBPreferredSharesIssuedToConsultantAmount2
SeriesBPreferredSharesIssuedToConsultant3
SeriesBPreferredSharesIssuedToConsultantAmount3
StockIssuedDuringPeriodSharesIssuedForServices3
StockIssuedDuringPeriodValueIssuedForServices3
SaleOfStockConsiderationReceivedPerTransaction3
SaleOfStockConsiderationReceivedPerTransaction4
PreferredSharesOfSubsidiaryIssuedToConsultants2
StockIssuedDuringPeriodSharesIssuedForServices4
StockIssuedDuringPeriodValueIssuedForServices4
SharesIssuedForAccruedExpenses2
SharesIssuedForAccruedExpensesAmount2
DebtInstrumentConvertibleBeneficialConversionFeature2
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature2
PreferredSharesOfSubsidiaryIssuedToConsultants3
Dividends, Cash
Noncontrolling Interest, Increase from Subsidiary Equity Issuance
Debt Disclosure [Text Block]
Income Tax Disclosure [Text Block]
Stockholders' Equity Note Disclosure [Text Block]
Income Tax, Policy [Policy Text Block]
Schedule of Debt [Table Text Block]
Comprehensive Income (Loss) [Table Text Block]
Property, Plant and Equipment, Gross
Deferred Tax Assets, Gross
Deferred Tax Assets, Valuation Allowance
Deferred Tax Assets, Net of Valuation Allowance
Debt, Current